Dasatinib News and Research

RSS
Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.
HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

Rare BCR-ABL fusions highlighted in CML

Rare BCR-ABL fusions highlighted in CML

Study may predict which glioblastoma patients may respond well to dasatinib drug treatment

Study may predict which glioblastoma patients may respond well to dasatinib drug treatment

Patient characteristics may guide TKI use in CML

Patient characteristics may guide TKI use in CML

High CIP2A may guide TKI choice for chronic phase CML

High CIP2A may guide TKI choice for chronic phase CML

CML guidelines highlight need for TKI switch timing, choice

CML guidelines highlight need for TKI switch timing, choice

Fourth-line bosutinib ‘appropriate’ after prior CML treatment failure, intolerance

Fourth-line bosutinib ‘appropriate’ after prior CML treatment failure, intolerance

Researchers identify new class of drugs that slows aging process

Researchers identify new class of drugs that slows aging process

Second-line bosutinib well tolerated by Japanese patients

Second-line bosutinib well tolerated by Japanese patients

Study shows targeted therapeutic after chemotherapy kills transitional cancer cells

Study shows targeted therapeutic after chemotherapy kills transitional cancer cells

PF-114 shows promise in therapy-resistant CML, Ph-positive ALL

PF-114 shows promise in therapy-resistant CML, Ph-positive ALL

Ponatinib ‘superior’ to sequential second-generation TKI treatment in CML

Ponatinib ‘superior’ to sequential second-generation TKI treatment in CML

Rapamycin and dasatinib combination may be beneficial in treating breast cancer, say scientists

Rapamycin and dasatinib combination may be beneficial in treating breast cancer, say scientists

EMA's CHMP adopts final opinion on ARIAD Pharmaceuticals' Iclusig (ponatinib)

EMA's CHMP adopts final opinion on ARIAD Pharmaceuticals' Iclusig (ponatinib)

Dasatinib: Leukemia drug shows promise for treating skin, breast and other cancers

Dasatinib: Leukemia drug shows promise for treating skin, breast and other cancers

Avillion initiates BOSULIF Phase 3 trial in patients with chronic phase Ph+ CML

Avillion initiates BOSULIF Phase 3 trial in patients with chronic phase Ph+ CML

Co-targeting strategies suggested for EGFR-TKI resistance in NSCLC

Co-targeting strategies suggested for EGFR-TKI resistance in NSCLC

Head and neck cancers associated with genetic alterations could be sensitive to existing cancer drug

Head and neck cancers associated with genetic alterations could be sensitive to existing cancer drug

FDA grants full approval of SYNRIBO for injection

FDA grants full approval of SYNRIBO for injection